Xembify: payments to doctors
Payments that named Xembify as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $3.1M
- Providers
- 5,085
- Transactions
- 25,848
- Average per transaction
- $118
The per-transaction average — $118 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 5,085 providers the average total is $601, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Grifols USA, LLC | $2,971,494 | 97.2% |
| Grifols Shared Services North America, Inc. | $82,448 | 2.7% |
| Grifols Therapeutics LLC | $2,700 | 0.1% |